Dr Hoyles qualified in Cambridge, and trained in London centred around the Royal Brompton Hospital, before taking up her current appointment in the Oxford Centre for Respiratory Medicine in 2009. She completed a successful clinical and translational PhD project at the Royal Brompton and Royal Free Hospitals investigating the role of lung injury in scleroderma-associated lung fibrosis.
Her interests include lung fibrosis (scarring), asthma, chronic obstructive airways disease, lung infection, investigation of cough and breathlessness and a broad range of general respiratory and general medical conditions.
Dr Hoyles is the lead clinician for the Oxford Interstitial Lung Disease Service, and her unit is an NHS England recognised specialist centre for interstitial lung disease (ILD) and a Pirfenidone prescribing centre. Rachel has a national profile in ILD, is a regular speaker at national conferences. She is a current member of the ILD Specialist Advisory Group, advising the British Thoracic Society on national policy including NICE recommendations, has held an advisory role with the British Lung Foundation in forming a Patient Charter.
- Interstitial Lung Disease (ILD, lung scarring)
- Connective tissue diseases and the lung
- General Respiratory Medicine
- Oxford lead for postgraduate respiratory training
Family, travel and outdoor pursuits
Dr Hoyles’ active research interests include clinical trials in idiopathic pulmonary fibrosis (via the active UKCRC Oxford Respiratory Trials Unit), lung diseases associated with vasculitis, immunosuppressant strategies in lung disease associated with rheumatological problems, and imaging modalities in lung fibrosis.
She completed a successful clinical and translational PhD project in which she investigated the role of lung injury in scleroderma-associated lung fibrosis. The PhD research culminated in winning the British Thoracic Society Young Investigators Prize in 2008, and selection of her work to be presented at the American Thoracic Society ‘Outstanding science symposium: scientific breakthroughs of the year’ in 2008.
- Oxford Textbook of Rheumatology, The Respiratory System. Hoyles RK, Wells AU (book chapter) 2013.
- An Essential Role for Resident Fibroblasts in Experimental Lung Fibrosis Is Defined by Lineage-Specific Deletion of High-Affinity Type II Transforming Growth Factor ß Receptor, Hoyles RK et al. Am J Respir Crit Care Med. 2011.
- A multicenter, prospective, randomised, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. RK Hoyles et al. Arthritis Rheum 2006.
Rachel is currently Principal Investigator (PI) of four multi-national pharmaceutical trials in Idiopathic Pulmonary Fibrosis, is a Co-Investigator of a Vasculitis classification study, and has ongoing research interests in blood biomarkers of lung disease. She has published one of few multi-centre randomised controlled trials in connective tissue disease-associated pulmonary fibrosis.
- British Thoracic Society (BTS)
- Interstitial Lung Disease ILD Specialist Advisory Group BTS
- Royal College of Physicians
- British Medical Association
- Oxford Deanery Specialist Training Committee
Other post held
- Oxford Centre for Respiratory Medicine, Churchill Hospital
- Oxford Interstitial Lung Disease Service Lead Clinician
Insurers Dr Rachel Hoyles works with
Dr Rachel Hoyles works with the following private medical insurance providers:
- Aviva Health
- AXA PPP Healthcare
- Benenden Health
- CS Healthcare
- Exeter Family Friendly
Dr Rachel Hoyles does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.
Dr Rachel Hoyles does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.
Dr Rachel Hoyles does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.